Skip to main content

Hyperuricemia

5
Pipeline Programs
8
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
5
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 8 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
2 programs
1
Verinurad 9 mg+Febuxostat 80 mgPhase 21 trial
Uric acid levelN/A1 trial
Active Trials
NCT02502565Unknown150Est. Mar 2019
NCT03118739Completed60Est. Aug 2018
Kite Pharma
Kite PharmaCA - El Segundo
2 programs
2
ArhalofenatePhase 2
ArhalofenatePhase 2
InventisBio
InventisBioChina - Shanghai
1 program
1
D-0120Phase 21 trial
Active Trials
NCT05504083Completed121Est. May 2024
Kissei Pharmaceutical
Kissei PharmaceuticalJapan - Matsumoto City
1 program
1
KUX-1151Phase 21 trial
Active Trials
NCT02190786Completed
Teijin Pharma
Teijin PharmaJapan - Tokyo
1 program
FebuxostatN/ASmall Molecule1 trial
Active Trials
NCT01984749Unknown1,000
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
1 program
ArhalofenatePHASE_21 trial
Active Trials
NCT01416402Completed27Est. Oct 2011
Sanofi
SanofiPARIS, France
1 program
RasburicasePHASE_41 trial
Active Trials
NCT00302653Completed33

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SanofiRasburicase
InventisBioD-0120
AstraZenecaVerinurad 9 mg+Febuxostat 80 mg
Gilead SciencesArhalofenate
Teijin PharmaFebuxostat
AstraZenecaUric acid level

Clinical Trials (7)

Total enrollment: 1,391 patients across 7 trials

NCT00302653SanofiRasburicase

Rasburicase in Tumor Lysis Syndrome

Start: Feb 200633 patients
Phase 4Completed
NCT02190786Kissei PharmaceuticalKUX-1151

Phase II Exploratory Clinical Study of KUX-1151

Phase 2Completed
NCT05504083InventisBioD-0120

Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients

Start: Sep 2022Est. completion: May 2024121 patients
Phase 2Completed
NCT03118739AstraZenecaVerinurad 9 mg+Febuxostat 80 mg

Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria

Start: May 2017Est. completion: Aug 201860 patients
Phase 2Completed
NCT01416402Gilead SciencesArhalofenate

Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients

Start: Aug 2011Est. completion: Oct 201127 patients
Phase 2Completed
NCT01984749Teijin PharmaFebuxostat

Febuxostat for Cerebral and caRdiorenovascular Events prEvEntion stuDy

Start: Nov 20131,000 patients
N/AUnknown
NCT02502565AstraZenecaUric acid level

Musculoskeletal Ultrasound in Asymptomatic Hyperuricemia

Start: Jan 2012Est. completion: Mar 2019150 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.